MCL Literature Feed
18 papers on mantle cell lymphoma from PubMed. Updated daily.
In the phase 3 TRIANGLE trial for young, fit MCL, adding ibrutinib to induction immunochemotherapy improves failure-free survival, with noninvasive genotyping confirming its efficacy and treatment dynamics.
A new genomic model integrating mutations (e.g., TP53) and copy number variations improves risk stratification for elderly, newly diagnosed MCL patients treated with chemoimmunotherapy.
The phase 3 TRIANGLE trial shows adding ibrutinib to frontline chemoimmunotherapy and autologous transplant improves failure-free survival, establishing a new standard of care for young, fit MCL patients.
In the MCL0208 trial for young patients, IGHV mutation status and stereotyped receptors predicted outcomes after intensive chemoimmunotherapy and transplant, offering a new biomarker for frontline risk stratification.
Frontline ibrutinib-rituximab improves progression-free survival over immunochemotherapy in older MCL patients, establishing a new chemotherapy-free standard of care option.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This SHINE trial analysis shows ibrutinib's PFS benefit with BR is consistent across exposure levels, supporting dose reductions for toxicities like atrial fibrillation without compromising efficacy.
In elderly, frontline MCL, this SHINE secondary analysis shows achieving a complete response is critical for long-term PFS, and adding ibrutinib to BR significantly increases CR rates.
In untreated mantle cell lymphoma, adding acalabrutinib to bendamustine-rituximab significantly improves progression-free survival with manageable toxicity, offering a potentially safer chemoimmunotherapy combination than ibrutinib-based regimens.
The MCL35 gene expression assay identifies high-risk older patients who do not benefit from adding ibrutinib to bendamustine-rituximab, mandating alternative frontline strategies for this molecularly-defined subgroup.
Alternating R-DA-EDOCH/R-DHAP induction for young, newly diagnosed MCL patients achieved an 89% complete remission rate and high MRD negativity, offering a potent new frontline intensive chemotherapy option.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
In relapsed/refractory MCL, the phase 3 SYMPATICO trial established ibrutinib plus venetoclax as superior to ibrutinib alone, significantly improving median progression-free survival by nearly 10 months.
For younger MCL patients post-transplant, this phase III analysis shows conditional survival improves over time, especially after R-CHOP, providing data for dynamic prognostication and reinforcing intensive induction.
Analysis of the FIL MCL0208 trial shows that stem cell collection and subsequent hematological recovery are feasible and safe in young, fit MCL patients undergoing frontline autologous transplant consolidation.
Adding bortezomib to R-HAD chemotherapy for relapsed/refractory MCL significantly improved time to treatment failure (12 vs 2.6 months), providing a valuable option when BTK inhibitors are unavailable.
In young, newly diagnosed MCL patients, adding ibrutinib to chemoimmunotherapy improves failure-free survival, establishing a new standard and questioning the necessity of autologous stem cell transplant consolidation.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The phase 3 TRIANGLE trial established that adding ibrutinib to induction/maintenance allows omission of autologous transplant in young, fit MCL patients, providing a new frontline, transplant-free standard.
Long-term follow-up confirms rituximab maintenance post-transplant significantly improves overall survival in young, fit MCL patients, establishing this as a standard of care in the frontline setting.
In elderly MCL, rituximab maintenance benefits even MRD-negative patients post-induction, arguing against de-escalation and identifying MRD-positivity as a high-risk feature needing better consolidation.